Healthcare Services

Global Humira Biosimilar Market to Reach $6.53B by 2030 at 12.2% CAGR

April 22, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Humira Biosimilar Market Over The 2026–2030 Period?

The humira biosimilar market size has expanded significantly in recent years. It is forecast to increase from $3.67 billion in 2025 to $4.12 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.3%. The historical period’s growth can be linked to the patent expiry of humira, the high treatment costs of branded biologics, the increasing prevalence of autoimmune diseases, regulatory support for biosimilar approvals, and payer pressure to reduce biologic drug spending.

The Humira biosimilar market is projected to experience substantial expansion in the coming years. This market is set to reach a valuation of $6.53 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.2%. This anticipated growth during the forecast period is primarily driven by factors such as the broader integration of biosimilars into clinical practice, expanded reimbursement options for these products, enhanced physician trust in their effectiveness, an increase in interchangeable biosimilar approvals, and growing initiatives aimed at improving patient access to affordable biologics. Key trends anticipated during this period encompass the wider utilization of adalimumab biosimilars for various autoimmune conditions, a heightened emphasis on managing costs associated with biologic treatments, greater acceptance of interchangeable biosimilars among healthcare providers, an escalating need for formulations that are high-concentration and citrate-free, and a rise in competitive intensity among companies manufacturing biosimilars.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/humira-biosimilar-global-market-report

Which Drivers Are Supporting The Humira Biosimilar Market Growth?

The humira biosimilar market is projected to expand due to the escalating prevalence of autoimmune diseases. These conditions manifest when the immune system erroneously targets and attacks the body’s own healthy cells, tissues, or organs. The growing incidence of autoimmune diseases is associated with environmental pollution, which disrupts the immune system and increases the risk of autoimmune reactions. Humira biosimilars operate by blocking tumor necrosis factor (TNF), a protein that triggers inflammation in autoimmune diseases. This action helps to diminish the immune response, thereby easing symptoms and preventing harm to healthy tissues. For instance, in August 2024, data from Public Health Scotland, a national organization located in Scotland, indicated that the Scottish Multiple Sclerosis Register (SMSR) recorded 455 newly diagnosed MS patients in 2023. Thus, the increasing occurrence of autoimmune disorders is a significant factor driving the expansion of the humira biosimilar market.

How Is The Humira Biosimilar Market Categorized Across Its Segment Groups?

The humira biosimilar market covered in this report is segmented –

1) By Product Type: Adalimumab Biosimilars, High-Concentration Adalimumab Biosimilars, Citrate-Free Adalimumab Biosimilars

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

3) By Application: Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Other Applications

Subsegments:

1) By Adalimumab Biosimilars: Citrate-Containing, Standard-Concentration Formulations, Citrate-Free, Standard-Concentration Formulations

2) By High-Concentration Adalimumab Biosimilars: Citrate-Containing High-Concentration Formulations, Citrate-Free High-Concentration Formulations

3) By Citrate-Free Adalimumab Biosimilars: Standard-Concentration Citrate-Free Formulations, High-Concentration Citrate-Free Formulations

Which Trends Are Expected To Impact The Humira Biosimilar Market?

Companies operating within the humira biosimilar market are concentrating on creating sophisticated products, such as tumor necrosis factor (TNF) blockers, to provide more economical choices for managing autoimmune conditions. Tumor necrosis factor (TNF) blockers are biological drugs that inhibit the action of TNF, a crucial protein involved in promoting inflammation. For instance, in July 2023, Organon & Co., a US-based pharmaceutical firm, collaborated with Samsung Bioepis Co., Ltd., a South Korea-based biotech company, to release HADLIMA, a biosimilar of Humira. HADLIMA is available in high-concentration (100 mg/mL) citrate-free and low-concentration (50 mg/mL) citrate-containing versions, mirroring the options of the originator Humira, with the intention of enhancing patient accessibility and affordability. The product is sold at a substantial reduction, approximately 85% below Humira’s list price, and includes patient assistance schemes. This introduction, enabled by a global settlement allowing U.S. supply, represents a significant step in broadening treatment options for chronic autoimmune diseases across the U.S.

Which Firms Are Influencing Competition In The Humira Biosimilar Market?

Major companies operating in the humira biosimilar market are Amgen Inc., Pfizer Inc., Samsung Biologics, Biocon Limited, Celltrion Inc., Boehringer Ingelheim GmbH, Sandoz Group AG, Fresenius Kabi AG, Alvotech, Coherus BioSciences Inc., Zydus Lifesciences Ltd., Hetero Drugs Ltd., LG Chem Ltd., Torrent Pharmaceuticals Ltd., Fujifilm Holdings Corporation, Teva Pharmaceutical Industries Ltd., Merck KGaA, Organon & Co., Cipla Limited, Dr. Reddy’s Laboratories Ltd.

Get The Full Humira Biosimilar Market Report:

https://www.thebusinessresearchcompany.com/report/humira-biosimilar-global-market-report

Which Region Holds The Highest Market Share In The Humira Biosimilar Market?

North America was the largest region in the humira biosimilar market in 2025. The regions covered in the humira biosimilar market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Humira Biosimilar Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/humira-biosimilar-global-market-report

Browse Through More Reports Similar to the Global Humira Biosimilar Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Humic Based Biostimulants Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/humic-based-biostimulants-market-global-market-report

Biosimulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795